Endocyte (NASDAQ: ECYT) shares got hammered today on the disappointing news that partner Merck (MRK 0.37%) decided to hand back rights to vintafolide and leave the company to go it alone.
Endocyte is waiting for more data from a phase 2b trial in non-small cell lung cancer before deciding what vintafolide's future should be. The drug recently flopped in a phase 3 trial for platinum-resistant ovarian cancer.
So, with a lot of optimism priced out of the stock, is this a buying opportunity?
In the video below, health care analysts Michael Douglass and David Williamson let you know what they think.
